🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

An International Public Health Issue

The sexually transmitted infection are increasing around the world, with estimates suggesting in excess of 82 million infections each year. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the context of rising global incidence, the spread of superbugs and the very limited treatment choices at this time.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Global Access

Based on findings released by a major medical journal, zoliflodacin eradicated more than 90% of cases of the STI. This establishes an comparable level with the current standard treatment, which involves an injection and a pill. The research involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in many developing nations.

Medical professionals on the front lines have shared hope. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the illness for individuals and to halt the transmission of highly drug-resistant gonorrhoea worldwide.